文献速递头颈部肿瘤放疗放疗物理与技术

SPECT/CT引导下选择性淋巴结照射治疗头颈癌肿瘤学安全且毒性更低:一种可能改变实践的方案

SPECT/CT-guided elective nodal irradiation for head and neck cancer is oncologically safe and less toxic: A potentially practice-changing approach.
PubMed 文献 · Radiother Oncol · 2020-03-30

这项前瞻性原理验证试验纳入50例侧方T1-3N0-2bM0头颈鳞癌患者,采用瘤周注射99mTc-纳米胶体后SPECT/CT引导对侧阴性颈选择性淋巴结照射(ENI)。中位随访33个月,对侧区域失败仅1例(2%;95%CI 0-6%)。与1:1匹配的历史双侧ENI队列相比,SPECT/CT引导ENI显著降低≥2级吞咽困难(54% vs 82%;p<0.001)、管饲(10% vs 50%;p<0.001)和晚期≥2级口干(9% vs 54%;p<0.001),并改善健康相关生活质量。

要点

  • SPECT/CT引导对侧阴性颈ENI的2年对侧区域失败率为2%(95%CI 0-6%)。
  • 与双侧ENI相比,≥2级吞咽困难(54% vs 82%)、管饲(10% vs 50%)、晚期≥2级口干(9% vs 54%)均显著降低。
  • EORTC QLQ-C30汇总评分及QLQ-HN35吞咽、口干子量表显示有临床意义的生活质量获益。

核心结论

  • SPECT/CT引导的对侧阴性颈ENI与低对侧区域失败风险相关,并较双侧ENI显著降低吞咽困难、管饲和晚期口干,改善生活质量。

研究设计与样本

  • 前瞻性原理验证试验(NCT02572661)纳入50例侧方T1-3N0-2bM0头颈鳞癌(口咽、口腔、喉、下咽)患者,瘤周注射99mTc-纳米胶体后行SPECT/CT。
  • 无对侧淋巴引流者仅行同侧ENI;对侧仅一个热点的ENI限于含该热点的区域。
  • 主要终点为2年对侧区域失败(CRF)发生率;毒性和生活质量与1:1匹配的接受标准双侧ENI(B-ENI)且计划和治疗技术相同的历史队列比较。

主要发现

  • 中位随访33个月(范围18-45),50例中1例(2%;95%CI 0-6%)出现对侧区域失败。
  • 与匹配的B-ENI组相比,SPECT/CT引导ENI组≥2级吞咽困难发生率54% vs 82%(p<0.001)。
  • 管饲发生率10% vs 50%(p<0.001);晚期≥2级口干发生率9% vs 54%(p<0.001)。
  • EORTC QLQ-C30汇总评分及QLQ-HN35吞咽、口干子量表观察到显著且有临床意义的生活质量获益。

临床怎么用

  • 对侧临床阴性颈的头颈鳞癌患者,可考虑采用SPECT/CT引导ENI以降低吞咽困难、管饲和晚期口干并改善生活质量。
  • 本方案可能改变头颈癌选择性淋巴结照射的实践,但需在更广泛人群中进一步验证。

局限性

  • 样本量50例,随访中位33个月(范围18-45),为前瞻性单臂设计与历史对照比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Bilateral elective nodal irradiation (ENI) remains the standard treatment for head and neck squamous cell carcinoma (HNSCC). Unilateral ENI could reduce treatment toxicity and improve health-related quality-of-life (HRQOL). This prospective proof-of-principle trial (NCT02572661) investigated the feasibility, safety and clinical benefits of SPECT/CT-guided ENI of the node-negative contralateral neck. MATERIALS AND METHODS: Patients with lateralized T1-3N0-2bM0 HNSCC of the oropharynx, oral cavity, larynx and hypopharynx underwent SPECT/CT after peritumoral 99mTc-nanocolloid injection. Patients without contralateral lymph drainage received ipsilateral ENI only. If lymph drainage to only one contralateral hot spot was visible, ENI to the contralateral neck would be limited to only the level containing the hot spot. The primary endpoint was the incidence of contralateral regional failure (CRF) at 2 years. Toxicity and HRQOL were compared with a 1:1 matched historical cohort that received standard bilateral ENI (B-ENI) with identical planning and treatment techniques. RESULTS: Fifty patients were treated with SPECT/CT-guided ENI. After a median follow-up of 33 months (range 18-45), CRF was observed in one patient (2%; 95% confidence interval: 0-6%). Compared to the matched B-ENI group, patients treated with SPECT/CT-guided ENI had significantly lower incidences of grade ≥2 dysphagia (54% vs. 82%; p < 0.001), tube feeding (10% vs. 50%; p < 0.001) and late grade ≥2 xerostomia (9% vs. 54%; p < 0.001). Significant and clinically relevant HRQOL benefits of SPECT/CT-guided ENI were observed on the EORTC QLQ-C30 summary score, and QLQ-HN35 swallowing and dry mouth subscales. CONCLUSION: SPECT/CT-guided ENI is associated with a low risk of contralateral regional failure. Compared to B-ENI, SPECT/CT-guided ENI significantly reduces dysphagia, feeding tube placement, and late xerostomia and improves HRQOL.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. de Veij Mestdagh PD, Walraven I, Vogel WV, et al. SPECT/CT-guided elective nodal irradiation for head and neck cancer is oncologically safe and less toxic: A potentially practice-changing approach. Radiother Oncol. 2020. PMID: 32240908. doi:10.1016/j.radonc.2020.03.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。